{
    "nct_id": "NCT06564038",
    "official_title": "A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies",
    "inclusion_criteria": "Master Inclusion Criteria applicable to all substudies:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Contraception during treatment and at least 6 months after final dose.\n* Confirmed CD19 expression if prior anti-CD19 therapy.\n\nSubstudy 1 Specific Inclusion Criteria:\n\n* Participants with CLL must require treatment according to the international workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.\n* SLL: at least 1 measurable site per Lugano.\n* Absolute lymphocytes <10,000.\n* Cohort 1A: at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i).\n* Cohort 1B: at least 1 prior line of therapy and is BTKi-sensitive.\n\nSubstudy 2 Specific Inclusion Criteria:\n\n* MCL diagnosis per WHO.\n* Clinical Stage II, III, or IV by Ann Arbor Classification.\n* At least 1 measurable site per Lugano\n* ALC < 10,000.\n* Cohort 2A: Relapse or progressed after 2 or more lines of therapy including BTKi.\n* Cohort 2B: Relapse or progressed after 1 or more line of therapy, not including a BTKi.\n\nSubstudy 3 Specific Inclusion Criteria:\n\n* Large B-cell lymphoma per WHO 2022.\n* R/R B-NHL after at least 1 prior line of therapy.\n* International Prognostic Index (IPI) 2-5.\n* At least 1 measurable site as per Lugano.\n* Left ventricular ejection fraction (LVEF) >50%.\n* Contraception at least 12 months after last dose of R-CHOP or 6 months after last dose of AZD0486.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Master Exclusion Criteria applicable to all substudies:\n\n* central nervous system (CNS) lymphoma.\n* Surgery within 14 days of study drug.\n* Clinically significant cardiovascular (CV) disease.\n* Unresolved Grade >2 AEs from prior anticancer therapy (except alopecia or fatigue).\n* Any anticancer therapy within 5 half-lives or 21 days (whichever is shorter) prior to treatment.\n* Radiation therapy within 28 days.\n* Prior CAR-T or auto-haematopoietic stem cell transplant (HSCT) within 12 weeks or prior T-cell engager (TCE) within 8 weeks.\n* Prior Grade > 3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) event.\n\nSubstudy 1 Specific Exclusion Criteria:\n\n* CLL transformation to more aggressive lymphoma\n* Cohort 1B: bleeding diathesis, CYP3A inhibitor or inducer, history of ICH or stroke within 6 months, GI malabsorption, receiving vitamin K antagonist\n\nSubstudy 2 Specific Exclusion Criteria:\n\n* Cohort 2B: bleeding diathesis, CYP3A inhibitor or inducer, history of ICH or stroke within 6 months, GI malabsorption, receiving vitamin K antagonist\n\nSubstudy 3 Specific Exclusion Criteria:\n\n* Mediastinal grey-zone lymphoma, Burkitt, Richter's transformation, primary effusion large B-cell lymphoma (LBCL)\n* Cumulative dose of anthracycline >150 mg/m2",
    "miscellaneous_criteria": ""
}